Fate Therapeutics (FATE) Research & Development (2012 - 2026)

Fate Therapeutics has reported Research & Development for 15 years, with the latest figure at $24.7 million in Q1 2026.

• For the quarter ending Q1 2026, Research & Development fell 15.21% year-over-year to $24.7 million; the trailing twelve-month figure through Mar 2026 stood at $103.4 million (down 21.67% YoY), and the FY2025 full-year result was $107.8 million, down 20.13% from the prior year.
• Research & Development for Q1 2026 stood at $24.7 million, down from $25.4 million in the prior quarter.
• The five-year high for Research & Development was $87.2 million in Q4 2022, with the low at $24.7 million in Q1 2026.
• Historically, Research & Development has averaged $44.7 million across 5 years, with a median of $34.3 million in 2023.
• Annual changes were most pronounced in 2022 — Research & Development jumped 69.31% — and 2023, when it slumped 63.51%.
• Fate Therapeutics' Research & Development stood at $87.2 million in 2022, then sank by 63.51% to $31.8 million in 2023, then advanced by 5.64% to $33.6 million in 2024, then dropped by 24.35% to $25.4 million in 2025, then slipped by 2.84% to $24.7 million in 2026.
• The last three Research & Development figures came in at $24.7 million (Q1 2026), $25.4 million (Q4 2025), and $25.8 million (Q3 2025), per Business Quant data.